Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study

被引:9
作者
Park, Min Young [1 ]
Yoon, Yong Sik [1 ]
Lee, Jong Lyul [1 ]
Park, Sang Hyoung [2 ]
Ye, Byong Duk [2 ]
Yang, Suk-Kyun [2 ]
Yu, Chang Sik [1 ]
机构
[1] Univ Coll Med, Asan Med Ctr, Dept Colon & Rectal Surg, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
关键词
Adipose tissue-derived stem cell; ASC; Biologics; Crohn's disease; Fistula; INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA; ANTI-TNF; INFLIXIMAB; THERAPY; TERM; CLASSIFICATION; ADALIMUMAB; 6-MERCAPTOPURINE; AZATHIOPRINE;
D O I
10.1186/s13287-021-02484-6
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: Perianal fistula is one of the most common complications in Crohn's disease, and various medical and surgical treatments are being tried. The aim of this study was to compare the perianal fistula closure rates following treatment with anti-tumor necrosis factor (TNF) agents or autologous adipose tissue-derived stem cell (auto-ASC) transplantation with Crohn's disease (CD). Methods: CD patients who underwent seton placement for perianal fistula from January 2015 to December 2019 at a tertiary referral center were retrospectively reviewed. Patients were divided into two groups, one that received sequential treatments with anti-TNF agents (anti-TNF group) and the other that underwent auto-ASC transplantation (stem cell group). Clinical variables and fistula closure rates were compared in the two groups. Results: Of the 69 patients analyzed, 39 were treated with anti-TNF agents and 30 underwent auto-ASC transplantation. Compared with the stem cell group, patients in the anti-TNF group were older (p=0.028), were more frequently male (p=0.019), had fistulas with more penetrating behavior (p=0.002), had undergone surgery more frequently (p=0.010), and had a shorter interval from seton placement to intended treatment (p<0.001). During a median follow-up of 46 months (range, 30-52.5 months), fistula closure rates were significantly faster (83.3% vs. 23.1%, p<0.001), and the mean interval from seton placement to fistula closure significantly shorter (14 vs. 37 months, p<0.001) in the stem cell than in the anti-TNF group. Three patients experienced fistula recurrence, all in the stem cell group. Conclusions: Medical treatment using anti-TNF agents and auto-ASC transplantation are feasible treatment options after seton placement for Crohn's perianal fistula. However, the closure rate was significantly faster and the time to closure significantly shorter in patients who underwent auto-ASC transplantation than medical treatment.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Avdagic Nesina, 2013, Med Glas (Zenica), V10, P211
  • [2] Anti- TNF- a therapies for the treatment of Crohn's disease: the past, present and future
    Berns, Marc
    Hommes, Daniel W.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (02) : 129 - 143
  • [3] Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab
    Bouguen, Guillaume
    Siproudhis, Laurent
    Gizard, Emmanuel
    Wallenhorst, Timothee
    Billioud, Vincent
    Bretagne, Jean-Francois
    Bigard, Marc-Andre
    Peyrin-Biroulet, Laurent
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) : 975 - +
  • [4] TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION
    BRAEGGER, CP
    NICHOLLS, S
    MURCH, SH
    STEPHENS, S
    MACDONALD, TT
    [J]. LANCET, 1992, 339 (8785) : 89 - 91
  • [5] Long-Term Results of Adipose-Derived Stem Cell Therapy for the Treatment of Crohn's Fistula
    Cho, Yong Beom
    Park, Kyu Joo
    Yoon, Sang Nam
    Song, Kee Ho
    Kim, Do Sun
    Jung, Sang Hun
    Kim, Mihyung
    Jeong, Hee Young
    Yu, Chang Sik
    [J]. STEM CELLS TRANSLATIONAL MEDICINE, 2015, 4 (05) : 532 - 537
  • [6] Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment
    de Groof, E. J.
    Sahami, S.
    Lucas, C.
    Ponsioen, C. Y.
    Bemelman, W. A.
    Buskens, C. J.
    [J]. COLORECTAL DISEASE, 2016, 18 (07) : 667 - 675
  • [7] Does infliximab infusion impact results of operative treatment for crohn's perianal fistulas?
    Gaertner, Wolfgang B.
    Decanini, Alejandra
    Mellgren, Anders
    Lowry, Ann C.
    Goldberg, Stanley M.
    Madoff, Robert D.
    Spencer, Michael P.
    [J]. DISEASES OF THE COLON & RECTUM, 2007, 50 (11) : 1754 - 1760
  • [8] A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation
    García-Olmo, D
    García-Arranz, M
    Herreros, D
    Pascual, I
    Peiro, C
    Rodríguez-Montes, JA
    [J]. DISEASES OF THE COLON & RECTUM, 2005, 48 (07) : 1416 - 1423
  • [9] Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease:: a new cell-based therapy
    García-Olmo, D
    García-Arranz, M
    García, LG
    Cuellar, ES
    Blanco, IF
    Prianes, LA
    Montes, JAR
    Pinto, FL
    Marcos, DH
    García-Sancho, L
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (05) : 451 - 454
  • [10] Recurrent anal fistulae: Limited surgery supported by stem cells
    Garcia-Olmo, Damian
    Guadalajara, Hector
    Rubio-Perez, Ines
    Herreros, Maria Dolores
    de-la-Quintana, Paloma
    Garcia-Arranz, Mariano
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (11) : 3330 - 3336